Sign in
Taking people in United StatesPhase 1/2

Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury

Key facts

Who runs it
University of Arizona
Where
Tucson, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
90 people, planned
Started
28 May 2024
Expected to end
Sept 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Angiotensin (1-7)
  • Sterile saline
Record updated
11 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Participant or representative willing to provide informed consent
  • Age 18 years or older at time of enrollment
  • Traumatically induced head injury resulting from insult to head from an external force
  • Clinical diagnosis of acute intracranial lesion based on neuroradiologist report. CT scan and report must be available
  • Moderate or severe traumatic brain injury (TBI) defined as Glasgow Coma Scale (GCS) score on trauma presentation of 12 or less. In general: Moderate TBI will be defined as loss of consciousness between 30 minutes and 24 hours and GCS between 9 and 12. Severe TBI will be defined as loss of consciousness > 24 hours and GCS ≤ 9
  • Enrollment within 48 hours of TBI

Who cannot take part

  • Female of childbearing potential or sexually active male who is not willing to use an acceptable method of birth control for the treatment period and 7 days after the last dose of the study drug
  • Participation in another clinical study involving investigational product within 30 days prior to study enrollment
  • History of neurodegenerative disease or disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, or brain tumors that would impact cognitive testing
  • Time of injury cannot be determined
  • Neurosurgery within the last 30 days
  • Contraindication to having an MRI
  • Pregnant or lactating female
  • If in the opinion of the investigator, candidate is unsuitable for participation in the study

Where in United States

  • University of ArizonaTucson, United StatesContact: Clinical Research CoordinatorTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to test the safety of the drug Angiotensin (1-7) and learn whether it works well as a treatment in people who have suffered a moderate to severe traumatic brain injury (TBI).

Read full original descriptionShow less

The main questions this trial aims to answer are:

* Is Angiotensin (1-7) safe? * Does Angiotensin (1-7) improve mental functioning and reduce physical signs of brain damage in people who have suffered a moderate to severe TBI?

Participants will:

* Complete 21 days of study treatment consisting of a once-daily injection. * Provide blood samples. * Undergo two magnetic resonance imaging (MRI) scans of the brain. * Complete specific tasks and questionnaires that allow researchers to evaluate the participant's brain and psychological functioning.

Researchers will compare three groups: two groups that receive different doses of Angiotensin (1-7) and one group that receives a look-alike treatment with no active drug. This will allow researchers to see if the drug has any negative effects and whether it improves mental functioning and physical signs of brain damage after a TBI.

The 3 groups in the trial

  • Ang 1-7 100 mcg/kg/dayTreatment being tested

    Angiotensin I/II (1-7) acetate will be delivered as a subcutaneous injection at a dose of 100 micrograms per kilogram per day for 21 days.

    Treatment: Angiotensin (1-7)

  • Ang 1-7 200 mcg/kg/dayTreatment being tested

    Angiotensin I/II (1-7) acetate will be delivered as a subcutaneous injection at a dose of 200 micrograms per kilogram per day for 21 days.

    Treatment: Angiotensin (1-7)

  • PlaceboPlacebo, for comparison

    Sterile saline (NaCl) will be delivered as a subcutaneous injection for 21 days.

    Treatment: Sterile saline

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo Controlled Study of the Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury (TBI)
Record updated
11 August 2026